Clinical Outcomes of Stereotactic Body Radiation Therapy for Early-stage Non-small Cell Lung Cancer

Yutaro Tasaki; Kazuto Ashizawa; Daisuke Nakamura; Takashi Mizowaki; Seiji Nagashima; Toshifumi Fujimoto; Masataka Uetani

doi:10.21873/cdp.10202

Clinical Outcomes of Stereotactic Body Radiation Therapy for Early-stage Non-small Cell Lung Cancer

Cancer Diagn Progn. 2023 Mar 3;3(2):201-207. doi: 10.21873/cdp.10202. eCollection 2023 Mar-Apr.

Authors

Yutaro Tasaki^{1

2}, Kazuto Ashizawa^{2

3}, Daisuke Nakamura¹, Takashi Mizowaki⁴, Seiji Nagashima⁵, Toshifumi Fujimoto¹, Masataka Uetani⁶

Affiliations

¹ Department of Radiology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
² Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
³ Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
⁴ Department of Radiology, Sasebo City General Hospital, Nagasaki, Japan.
⁵ Department of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
⁶ Department of Radiological Science, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Abstract

Background/aim: To investigate the clinical outcomes of stereotactic body radiotherapy (SBRT) in patients with early-stage non-small cell lung cancer (NSCLC).

Patients and methods: Among consecutive patients with early-stage NSCLC who received SBRT between November 2009 and September 2019, those with cT1-2N0M0 staged by the UICC TNM classification and staging system for lung cancer were retrospectively analyzed.

Results: Fifty-three patients with early-stage NSCLC received SBRT. The median follow-up period was 29 months (range=2-105 months). Twenty-one lung tumors were clinically diagnosed as early-stage primary lung cancers without histological confirmation. Histological examinations revealed adenocarcinoma in 24 patients and squamous cell carcinoma in 8. Two- and 5-year local control, cancer-specific survival, progression-free survival (PFS), and overall survival (OS) rates were 94.4 and 94.4%; 94.6 and 90.8%; 69.0 and 43.3%; and 80.0 and 59.3%, respectively. In a univariate analysis, the T stage, histology, and type of pulmonary nodule correlated with PFS and OS.

Conclusion: Good clinical outcomes were achieved by patients with early-stage NSCLC who received SBRT.

Keywords: Stereotactic body radiotherapy; non-small cell lung cancer; radiotherapy.